{
  "approved_at_utc": null,
  "subreddit": "investing",
  "selftext": "There are around 800 publicly listed biotech companies, double the number from just a few years ago. The Biotech industry has been hit particularly hard by the broad market decline. The SPDR S&amp;P Biotech Index is down over 50% from it's February 2021 peak. The FDA has been rejecting a record amount of companies. A few years ago, 60% of clinical trials were positive. That number has dropped to less than 20% as of late, signaling the ease of funding for companies whose science was too early-stage. The explosion of publicly listed biotech companies recently seems to be a signal of mania, but mania produces overreactions, and overreactions present opportunities. Just over 20% of companies listed on the Nasdaq Biotech Index are currently trading for below cash.\n\nThe space should be approached with extreme caution. While many companies are trading at negative enterprise values, much of those that are, only have 2 years of cash left. Rising rates could hasten the rate of cash burn, and refinancing or issuing new debt may be very difficult or impossible. If bottom-fishing's your thing, here are the tickers from the NBI trading below their cash holdings. (Data pulled from Yahoo Finance, so take it with a grain of salt)\n\n1. 89bio: **ETNB**\n2. Achilles Therapeutics ADR: **ACHL**\n3. Acumen Pharma CMN: **ABOS**\n4. Adaptimmune Therapeutics: **ADAP**\n5. Adverum Biotechnologies: **ADVM**\n6. Akouos Inc.: **AKUS**\n7. Alector, Inc.: **ALEC**\n8. Aligos Therapeutics: **ALGS**\n9. Allakos, Inc.: **ALLK**\n10. Annexon, Inc.: **ANNX**\n11. Applied Therapeutics: **APLT**\n12. Atea Pharma: **AVIR**\n13. Autolus Therapeutics: **AUTL**\n14. Avrobio, Inc.: **AVRO**\n15. BioAtla: **BCAB**\n16. Biomea Fusion: **BMEA**\n17. Black Diamond Therapeutics: **BDTX**\n18. Bolt Therapeutics: **BOLT**\n19. Cabaletta Bio: **CABA**\n20. Centessa Pharmaceuticals: **CNTA**\n21. Connect Biopharma Holdings: **CNTB**\n22. Cortexyme, Inc.: **CRTX**\n23. Corvus Pharmaceuticals: **CRVS**\n24. Curis, Inc.: **CRIS**\n25. Cyteir Therapeutics: **CYT**\n26. CytomX Therpaeutics: **CTMX**\n27. Decibel Therapeutics: **DBTX**\n28. Dyne Therapeutics: **DYN**\n29. Forma Therapeutics: **FMTX**\n30. Frequency Therapeutics: **FREQ**\n31. Galapagos NV: **GLPG (-1.37B)**\n32. Gracell Biotechnologies: **GRCL**\n33. Graphite Bio: **GRPH**\n34. Gritstone Bio: **GRTS**\n35. Harpoon Therapeutics: **HARP**\n36. Homology Medicines: **FIXX**\n37. Ikena Oncology: **IKNA**\n38. Immuneering Corporation: **IMRX**\n39. Immunovant: **IMVT**\n40. Infinity Pharmaceuticals: **INFI**\n41. Iteos Therapeutics: **ITOS**\n42. Kodiak Sciences: **KOD**\n43. Kronos Bio: **KRON**\n44. Landos Biopharma: **LABP**\n45. Larimar Therapeutics: **LRMR**\n46. Leap Therapeutics: **LPTX**\n47. Magenta Therapeutics: **MGTA**\n48. Mereo Biopharma Group: **MREO**\n49. Molecular Templates: **MTEM**\n50. Mustang Bio: **MBIO**\n51. Neoleukin Therapeutics: **NLTX**\n52. Nextcure Inc.: **NXTC**\n53. NRX Pharmaceuticals: **NRXP**\n54. Olema Pharmaceuticals: **OLMA**\n55. Omega Therapeutics: **OMGA**\n56. Oncorus, Inc.: **ONCR**\n57. Oric Pharmaceuticals: **ORIC**\n58. Ovid Therapeutics: **OVID**\n59. Passage Bio: **PASG**\n60. Personalis, Inc.: **PSNL**\n61. Poseida Therapeutics: **PSTX**\n62. Precision Biosciences: **DTIL**\n63. Prelude Therapeutics: **PRLD**\n64. Rain Therapeutics: **RAIN**\n65. Rhythm Pharmaceuticals: **RYTM**\n66. Sensei Bio: **SNSE**\n67. Sera Prognostics: **SERA**\n68. Sesen Bio: **SESN**\n69. Shattuck Labs: **STTK**\n70. Silverback Therapeutics: **SBTX**\n71. Singular Genomics Systems: **OMIC**\n72. Solid Biosciences: **SLDB**\n73. Spero Therapeutics: **SPRO**\n74. Syros Pharmaceuticals: **SYRS**\n75. TCR2 Therapeutics: **TCRR**\n76. Terns Pharmaceuticals: **TERN**\n77. Tonix Pharmaceuticals: **TNXP**\n78. Viracta Therapeutics: **VIRX**\n79. Wave Life Sciences: **WVE**\n80. Werewolf Therapeutics: **HOWL**\n\nMany of these names have fallen over 70% from their 52-week highs. I also wonder if well-capitalized large players in the pharmaceutical space could be value plays, since these companies will most likely be the ones capitalizing on purchasing talent, Intellectual Property, or outright entire companies. Big Pharma has the capital to purchase much of the entire emerging pharma sector, and at potentially large discounts.",
  "author_fullname": "t2_qxsxmjo",
  "saved": false,
  "mod_reason_title": null,
  "gilded": 0,
  "clicked": false,
  "title": "After the precipitous decline, there may be significant value in the Biotech industry",
  "link_flair_richtext": [],
  "subreddit_name_prefixed": "r/investing",
  "hidden": false,
  "pwls": 6,
  "link_flair_css_class": null,
  "downs": 0,
  "top_awarded_type": null,
  "hide_score": false,
  "name": "t3_v7afrq",
  "quarantine": false,
  "link_flair_text_color": "dark",
  "upvote_ratio": 0.84,
  "author_flair_background_color": null,
  "subreddit_type": "public",
  "ups": 49,
  "total_awards_received": 0,
  "media_embed": {},
  "author_flair_template_id": null,
  "is_original_content": false,
  "user_reports": [],
  "secure_media": null,
  "is_reddit_media_domain": false,
  "is_meta": false,
  "category": null,
  "secure_media_embed": {},
  "link_flair_text": null,
  "can_mod_post": false,
  "score": 49,
  "approved_by": null,
  "is_created_from_ads_ui": false,
  "author_premium": false,
  "thumbnail": "",
  "edited": false,
  "author_flair_css_class": null,
  "author_flair_richtext": [],
  "gildings": {},
  "content_categories": null,
  "is_self": true,
  "mod_note": null,
  "created": 1654642905,
  "link_flair_type": "text",
  "wls": 6,
  "removed_by_category": null,
  "banned_by": null,
  "author_flair_type": "text",
  "domain": "self.investing",
  "allow_live_comments": false,
  "selftext_html": "&lt;!-- SC_OFF --&gt;&lt;div class=\"md\"&gt;&lt;p&gt;There are around 800 publicly listed biotech companies, double the number from just a few years ago. The Biotech industry has been hit particularly hard by the broad market decline. The SPDR S&amp;amp;P Biotech Index is down over 50% from it&amp;#39;s February 2021 peak. The FDA has been rejecting a record amount of companies. A few years ago, 60% of clinical trials were positive. That number has dropped to less than 20% as of late, signaling the ease of funding for companies whose science was too early-stage. The explosion of publicly listed biotech companies recently seems to be a signal of mania, but mania produces overreactions, and overreactions present opportunities. Just over 20% of companies listed on the Nasdaq Biotech Index are currently trading for below cash.&lt;/p&gt;\n\n&lt;p&gt;The space should be approached with extreme caution. While many companies are trading at negative enterprise values, much of those that are, only have 2 years of cash left. Rising rates could hasten the rate of cash burn, and refinancing or issuing new debt may be very difficult or impossible. If bottom-fishing&amp;#39;s your thing, here are the tickers from the NBI trading below their cash holdings. (Data pulled from Yahoo Finance, so take it with a grain of salt)&lt;/p&gt;\n\n&lt;ol&gt;\n&lt;li&gt;89bio: &lt;strong&gt;ETNB&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Achilles Therapeutics ADR: &lt;strong&gt;ACHL&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Acumen Pharma CMN: &lt;strong&gt;ABOS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Adaptimmune Therapeutics: &lt;strong&gt;ADAP&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Adverum Biotechnologies: &lt;strong&gt;ADVM&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Akouos Inc.: &lt;strong&gt;AKUS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Alector, Inc.: &lt;strong&gt;ALEC&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Aligos Therapeutics: &lt;strong&gt;ALGS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Allakos, Inc.: &lt;strong&gt;ALLK&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Annexon, Inc.: &lt;strong&gt;ANNX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Applied Therapeutics: &lt;strong&gt;APLT&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Atea Pharma: &lt;strong&gt;AVIR&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Autolus Therapeutics: &lt;strong&gt;AUTL&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Avrobio, Inc.: &lt;strong&gt;AVRO&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;BioAtla: &lt;strong&gt;BCAB&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Biomea Fusion: &lt;strong&gt;BMEA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Black Diamond Therapeutics: &lt;strong&gt;BDTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Bolt Therapeutics: &lt;strong&gt;BOLT&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Cabaletta Bio: &lt;strong&gt;CABA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Centessa Pharmaceuticals: &lt;strong&gt;CNTA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Connect Biopharma Holdings: &lt;strong&gt;CNTB&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Cortexyme, Inc.: &lt;strong&gt;CRTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Corvus Pharmaceuticals: &lt;strong&gt;CRVS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Curis, Inc.: &lt;strong&gt;CRIS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Cyteir Therapeutics: &lt;strong&gt;CYT&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;CytomX Therpaeutics: &lt;strong&gt;CTMX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Decibel Therapeutics: &lt;strong&gt;DBTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Dyne Therapeutics: &lt;strong&gt;DYN&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Forma Therapeutics: &lt;strong&gt;FMTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Frequency Therapeutics: &lt;strong&gt;FREQ&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Galapagos NV: &lt;strong&gt;GLPG (-1.37B)&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Gracell Biotechnologies: &lt;strong&gt;GRCL&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Graphite Bio: &lt;strong&gt;GRPH&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Gritstone Bio: &lt;strong&gt;GRTS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Harpoon Therapeutics: &lt;strong&gt;HARP&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Homology Medicines: &lt;strong&gt;FIXX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Ikena Oncology: &lt;strong&gt;IKNA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Immuneering Corporation: &lt;strong&gt;IMRX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Immunovant: &lt;strong&gt;IMVT&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Infinity Pharmaceuticals: &lt;strong&gt;INFI&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Iteos Therapeutics: &lt;strong&gt;ITOS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Kodiak Sciences: &lt;strong&gt;KOD&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Kronos Bio: &lt;strong&gt;KRON&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Landos Biopharma: &lt;strong&gt;LABP&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Larimar Therapeutics: &lt;strong&gt;LRMR&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Leap Therapeutics: &lt;strong&gt;LPTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Magenta Therapeutics: &lt;strong&gt;MGTA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Mereo Biopharma Group: &lt;strong&gt;MREO&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Molecular Templates: &lt;strong&gt;MTEM&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Mustang Bio: &lt;strong&gt;MBIO&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Neoleukin Therapeutics: &lt;strong&gt;NLTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Nextcure Inc.: &lt;strong&gt;NXTC&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;NRX Pharmaceuticals: &lt;strong&gt;NRXP&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Olema Pharmaceuticals: &lt;strong&gt;OLMA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Omega Therapeutics: &lt;strong&gt;OMGA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Oncorus, Inc.: &lt;strong&gt;ONCR&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Oric Pharmaceuticals: &lt;strong&gt;ORIC&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Ovid Therapeutics: &lt;strong&gt;OVID&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Passage Bio: &lt;strong&gt;PASG&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Personalis, Inc.: &lt;strong&gt;PSNL&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Poseida Therapeutics: &lt;strong&gt;PSTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Precision Biosciences: &lt;strong&gt;DTIL&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Prelude Therapeutics: &lt;strong&gt;PRLD&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Rain Therapeutics: &lt;strong&gt;RAIN&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Rhythm Pharmaceuticals: &lt;strong&gt;RYTM&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Sensei Bio: &lt;strong&gt;SNSE&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Sera Prognostics: &lt;strong&gt;SERA&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Sesen Bio: &lt;strong&gt;SESN&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Shattuck Labs: &lt;strong&gt;STTK&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Silverback Therapeutics: &lt;strong&gt;SBTX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Singular Genomics Systems: &lt;strong&gt;OMIC&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Solid Biosciences: &lt;strong&gt;SLDB&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Spero Therapeutics: &lt;strong&gt;SPRO&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Syros Pharmaceuticals: &lt;strong&gt;SYRS&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;TCR2 Therapeutics: &lt;strong&gt;TCRR&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Terns Pharmaceuticals: &lt;strong&gt;TERN&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Tonix Pharmaceuticals: &lt;strong&gt;TNXP&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Viracta Therapeutics: &lt;strong&gt;VIRX&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Wave Life Sciences: &lt;strong&gt;WVE&lt;/strong&gt;&lt;/li&gt;\n&lt;li&gt;Werewolf Therapeutics: &lt;strong&gt;HOWL&lt;/strong&gt;&lt;/li&gt;\n&lt;/ol&gt;\n\n&lt;p&gt;Many of these names have fallen over 70% from their 52-week highs. I also wonder if well-capitalized large players in the pharmaceutical space could be value plays, since these companies will most likely be the ones capitalizing on purchasing talent, Intellectual Property, or outright entire companies. Big Pharma has the capital to purchase much of the entire emerging pharma sector, and at potentially large discounts.&lt;/p&gt;\n&lt;/div&gt;&lt;!-- SC_ON --&gt;",
  "likes": null,
  "suggested_sort": null,
  "banned_at_utc": null,
  "view_count": null,
  "archived": false,
  "no_follow": false,
  "is_crosspostable": false,
  "pinned": false,
  "over_18": false,
  "awarders": [],
  "media_only": false,
  "can_gild": false,
  "spoiler": false,
  "locked": false,
  "author_flair_text": null,
  "treatment_tags": [],
  "visited": false,
  "removed_by": null,
  "num_reports": null,
  "distinguished": null,
  "subreddit_id": "t5_2qhhq",
  "author_is_blocked": false,
  "mod_reason_by": null,
  "removal_reason": null,
  "link_flair_background_color": "",
  "id": "v7afrq",
  "is_robot_indexable": true,
  "report_reasons": null,
  "author": "Blondeandblemished",
  "discussion_type": null,
  "num_comments": 15,
  "send_replies": true,
  "whitelist_status": "all_ads",
  "contest_mode": false,
  "mod_reports": [],
  "author_patreon_flair": false,
  "author_flair_text_color": null,
  "permalink": "/r/investing/comments/v7afrq/after_the_precipitous_decline_there_may_be/",
  "parent_whitelist_status": "all_ads",
  "stickied": false,
  "url": "https://www.reddit.com/r/investing/comments/v7afrq/after_the_precipitous_decline_there_may_be/",
  "subreddit_subscribers": 2033702,
  "created_utc": 1654663794,
  "num_crossposts": 0,
  "media": null,
  "is_video": false,
  "original_created_utc": 1654642905,
  "the_new_excerpt": "There are around 800 publicly listed biotech companies, double the number from\njust a few years ago. The Biotech industry has been hit particularly hard by the\nbroad market decline. The SPDR S&P Biotech Index is down over 50% from it's\nFebruary 2021 peak. The FDA has been rejecting a record amount…",
  "localize": [
    {
      "locale": "ja",
      "the_new_excerpt": "上場しているバイオテクノロジー企業は約800社で、前年の2倍になっています。\n上場しているバイオ企業は約800社で、数年前の2倍に増えています。バイオテクノロジー産業は、特に市場の下落によって大きな打撃を受けています。\n特にバイオテクノロジー業界は、広範な市場の下落によって大きな打撃を受けています。SPDR S&P Biotech Indexは、年初の株価から50％以上下落しました。\n2021年2月のピークから50％以上下落しています。FDAは記録的な量の拒絶反応を示している...",
      "title": "急落の後、バイオテクノロジー産業には大きな価値があるかもしれない"
    },
    {
      "locale": "zh",
      "the_new_excerpt": "目前约有800家公开上市的生物技术公司，比几年前多出一倍。\n比几年前增加了一倍。生物技术行业在大盘下跌中受到的打击尤为严重。\n跌的打击。SPDR标准普尔生物技术指数从2021年2月的峰值下跌了50%以上。\n2021年2月的峰值下降了50%以上。美国食品和药物管理局一直在拒绝创纪录的...",
      "title": "在断崖式下跌之后，生物技术行业可能存在重大价值"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": "目前約有800家公開上市的生物技術公司，比幾年前多出一倍。\n比幾年前增加了一倍。生物技術行業在大盤下跌中受到的打擊尤爲嚴重。\n跌的打擊。SPDR標準普爾生物技術指數從2021年2月的峯值下跌了50%以上。\n2021年2月的峯值下降了50%以上。美國食品和藥物管理局一直在拒絕創紀錄的...",
      "title": "在斷崖式下跌之後，生物技術行業可能存在重大價值"
    }
  ]
}